surmount trial tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT ESC 2025: post-hoc SURMOUNT-5 data
Description
By promoting weight loss through appetite repression and increased fat metabolism, it provides a holistic approach to rotundity treatment, perfecting not only physical appearance but also overall health
Let us work through real examples
These data reflect exposure of 718 patients to MOUNJARO and a mean duration of exposure to MOUNJARO of 36.6 weeks
Transition timeline: last semaglutide dose, 1-2 week washout, tirzepatide restart at 2.5mg with 4-week titration steps
Confirm the new vial concentration
The quality is clearly high, and everything arrived well-packaged and fresh. Jessica M
